Prostate‐specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low‐dose‐rate brachytherapy or external beam radiotherapy for localized prostate cancer

Prostate‐specific antigen nadir (nPSA) after radiotherapy for localized prostate cancer has been investigated as a predictor. However, nPSA usually requires several years, limiting its clinical utility. We investigated the significance of nPSA within 12 months (nPSA12) after low‐dose‐rate prostate b...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishimura, Shuichi, Ohashi, Toshio, Momma, Tetsuo, Sakayori, Masanori, Eriguchi, Takahisa, Tanaka, Tomoki, Yamashita, Shoji, Kosaka, Takeo, Oya, Mototsugu, Shigematsu, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943430/
https://www.ncbi.nlm.nih.gov/pubmed/29577651
http://dx.doi.org/10.1002/cam4.1443

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943430/
https://www.ncbi.nlm.nih.gov/pubmed/29577651
http://dx.doi.org/10.1002/cam4.1443

Ejemplares similares